TY - JOUR
T1 - Immunotherapy in Pancreatic Adenocarcinoma
T2 - Beyond "copy/Paste
AU - Hester, Robert
AU - Mazur, Pawel K.
AU - McAllister, Florencia
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research Inc.. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Immunotherapy has dramatically changed the cancer treatment landscape during the past decade, but very limited efficacy has been reported against pancreatic cancer. Several factors unique to pancreatic cancer may explain the resistance: the well-recognized suppressive elements in the tumor microenvironment, the functional and structural barrier imposed by the stroma components, Tcell exhaustion, the choice of perhaps the wrong immune targets, and microbial factors including gut dysbiosis and the unexpected presence of tumor microbes. Furthermore, we discuss various strategies to overcome these barriers. _2021 The Authors; Published by the American Association for Cancer Research.
AB - Immunotherapy has dramatically changed the cancer treatment landscape during the past decade, but very limited efficacy has been reported against pancreatic cancer. Several factors unique to pancreatic cancer may explain the resistance: the well-recognized suppressive elements in the tumor microenvironment, the functional and structural barrier imposed by the stroma components, Tcell exhaustion, the choice of perhaps the wrong immune targets, and microbial factors including gut dysbiosis and the unexpected presence of tumor microbes. Furthermore, we discuss various strategies to overcome these barriers. _2021 The Authors; Published by the American Association for Cancer Research.
UR - http://www.scopus.com/inward/record.url?scp=85120506294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120506294&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-0900
DO - 10.1158/1078-0432.CCR-18-0900
M3 - Review article
C2 - 34193514
AN - SCOPUS:85120506294
SN - 1078-0432
VL - 27
SP - 6287
EP - 6297
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 23
ER -